Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Incidence, Risks, and Outcomes of Relapse Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma.

Michael R. Bishop, MD, Seth Steinberg, PhD, Nancy M. Hardy, MD, Steven Z. Pavletic, MD, Ronald E. Gress, MD, Rachel B. Salit, MD, Paula Layton, BSN, Daniel H. Fowler, MD

Blood (2010) 116 (21): 3451.

https://doi.org/10.1182/blood.V116.21.3451.3451

Published: 2010

Journal Articles

Allogeneic Hematopoetic Transplantation for CLL: Results of Combination Chemotherapy as Pre-Transplant Targeted Lymphocyte Depletion on Disease Response, Donor Chimerism, and Transplantation Outcomes.

Brian C Shaffer, MD, Marko Modric, David Liewehr, MS, Maryalice Stetler-Stevenson, MD, PhD, Diane C Arthur, MD, Seth Steinberg, PhD, Frances T Hakim, PhD, Kelly Bryant, Jeanne Odom, Paula Layton, BSN, Rachel B Salit, MD, Christoph Rader, PhD, Ronald E Gress, MD, Daniel H Fowler, MD, Michael R Bishop, MD, Steven Z Pavletic, MD

Blood (2010) 116 (21): 3476.

https://doi.org/10.1182/blood.V116.21.3476.3476

Published: 2010

Journal Articles

Clinical, Biochemical, and Radiographic Responses to Rituximab Combined with Liposomal Doxorubicin (R-Dox) in HIV-Infected Patients with Severe Kaposi Sarcoma-Associated Herpes Virus (KSHV) – Associated Multicentric Castleman's Disease.

Thomas Uldrick, MD, MS, Mark N. Polizzotto, MBBS, FRACP, FRCPA, Deirdre O'Mahony, Karen Aleman, Kathy Wyvill, Seth Steinberg, PhD, Stefania Pittaluga, MD, Richard F Little, MD, MPH, Robert Yarchoan, MD

Blood (2009) 114 (22): 1651.

https://doi.org/10.1182/blood.V114.22.1651.1651

Published: 2009

Journal Articles

Targeted Lymphocyte Depletion: A Personalized Approach to Achieve Rapid Complete Donor Chimerism and Enhance Graft-Versus-Tumor Effects Following Reduced Intensity Allogeneic Stem Cell Transplantation for High-Risk Hematologic Malignancies.

Rachel B. Salit, MD, Seth Steinberg, PhD, Daniel H. Fowler, MD, Jeanne Odom, RN, Kelly Bryant, RN, Michael R. Bishop, MD

Blood (2009) 114 (22): 656.

https://doi.org/10.1182/blood.V114.22.656.656

Published: 2009

Journal Articles

Targeted Lymphocyte Depletion Prior to Reduced Intensity Allogeneic Stem Cell Transplantation: A Personalized Approach to Facilitate Engraftment.

Rachel B. Salit, MD, Seth Steinberg, PhD, Daniel H. Fowler, Jeanne Odom, RN, Kelly Bryant, RN, Michael R. Bishop, MD

Blood (2009) 114 (22): 865.

https://doi.org/10.1182/blood.V114.22.865.865

Published: 2009

Journal Articles

Determinants of Platelet Counts in Patients with Chronic Graft Versus Host Disease.

Drazen Pulanic, MD, PhD, David Liewehr, MS, Seth Steinberg, PhD, Sandra A. Mitchell, CRNP, PhD, Kristin Baird, MD, Edward W. Cowen, MD, Galen Joe, MD, Kirsten M. Williams, MD, Daniele Avila, NP, Rachel B. Salit, MD, Niveen Atlam, Ashley Carpenter, RN, Fran Hakim, PhD, Michael Bishop, MD, Ronald E. Gress, MD, Steven Z. Pavletic, MD

Blood (2009) 114 (22): 2243.

https://doi.org/10.1182/blood.V114.22.2243.2243

Published: 2009

Journal Articles

Comparative Clinical and Biological Features of Primary Mediastinal B-Cell Lymphoma (PMBL) and Mediastinal Grey Zone Lymphoma (MGZL).

Kieron Dunleavy, MD, Stefania Pittaluga, MD, Kevin Tay, MD, Nicole Grant, MPH, Clara C Chen, MD, Margaret Shovlin, RN, Seth Steinberg, PhD, Louis M Staudt, MD, PhD, Elaine S Jaffe, MD, John E Janik, MD, Wyndham H Wilson, MD, PhD

Blood (2009) 114 (22): 106.

https://doi.org/10.1182/blood.V114.22.106.106

Published: 2009

Journal Articles

Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.

Kamal Sharma, DO, John E. Janik, MD, Deirdre O’Mahony, MD, Donn Stewart, MD, Stefania Pittaluga, MD, Maryalice Stetler-Stevenson, MD, PhD, Elaine S. Jaffe, MD, Mark Raffeld, MD, Thomas A. Fleisher, MD, Cathryn C. Lee, NP, Nicole Urquhart, MD, Seth Steinberg, PhD, Thomas A. Waldmann, MD, John C. Morris, MD

Blood (2008) 112 (11): 2010.

https://doi.org/10.1182/blood.V112.11.2010.2010

Published: 2008

Journal Articles

Gray Zone Lymphomas: Clinical and Histological Characteristics and Treatment with Dose-Adjusted-EPOCH-R

Kieron Dunleavy, MD, Stefania Pittaluga, MD, PhD, Nicole Grant, MPH, Seth Steinberg, PhD, Margaret Shovlin, RN, Kevin Tay, MD, John E. Janik, MD, Elaine S. Jaffe, M.D., Wyndham H. Wilson, MD, PhD

Blood (2008) 112 (11): 3590.

https://doi.org/10.1182/blood.V112.11.3590.3590

Published: 2008

Journal Articles

Long-Term Outcome of AIDS-Related Lymphoma Treated with Abbreviated Cycles of EPOCH-RR: A Prospective Study of 40 Patients

Kieron Dunleavy, MD, Richard Little, MD, Alan S. Wayne, MD, Nicole Grant, MPH, Stefania Pittaluga, MD, PhD, Elaine S. Jaffe, MD, Seth Steinberg, PhD, Robert Yarchoan, MD, PhD, Jorge A. Carrasquillo, MD, John E. Janik, MD, Wyndham H. Wilson, MD, PhD

Blood (2008) 112 (11): 3606.

https://doi.org/10.1182/blood.V112.11.3606.3606

Published: 2008

Journal Articles

Early Results of a Clinical Trial Using Targeted Oncolytic Virotherapy in Kaposi Sarcoma Herpes Virus (KSHV) Associated Multicentric Castleman’s Disease (MCD).

Deirdre O’Mahony, MD, Wendy Bernstein, MD, Kathy Wyvill, RN, Karen Aleman, RN, Denise Whitby, PhD, Seth Steinberg, PhD, Giovanna Tosato, MD, Stefania Pittaluga, MD, Elaine S. Jaffe, MD, Robert Yarchoan, MD, Richard F. Little, MD

Blood (2007) 110 (11): 514.

https://doi.org/10.1182/blood.V110.11.514.514

Published: 2007

Journal Articles

Burden of Illness in Chronic Graft vs. Host Disease - A Prospective Cohort Study.

Iskra Pusic, MD, John Dickinson, MD, PhD, Seth Steinberg, PhD, Jeanne Odom, RN, Niveen Atlam, Sandra Mitchell, RN, NP, Daniele Avila, RN, NP, Michael Krumlauf, RN, Kristin Baird, MD, Steven Pavletic, MD

Blood (2007) 110 (11): 1667.

https://doi.org/10.1182/blood.V110.11.1667.1667

Published: 2007

Journal Articles

Soluble BAFF Is Elevated Following Allogeneic SCT but Is Not an Early Predictor for the Development of cGVHD.

John D. Dickinson, MD, PhD, Iskra Pusic, MD, Christoph Rader, PhD, Seth Steinberg, PhD, Fran Hakim, PhD, Sivasubramanian Baskar, PhD, Steven Z. Pavletic, MD

Blood (2007) 110 (11): 167.

https://doi.org/10.1182/blood.V110.11.167.167

Published: 2007

Journal Articles

Ex-Vivo Reduction of Allograft T Cell Dose Does Not Prevent Acute Graft-vs-Host Disease after Reduced-Intensity Hematopoietic Stem Cell Transplantation.

Nancy M. Hardy, MD, Frances Hakim, PhD, Seth Steinberg, PhD, Michael Krumlauf, Rebecca Babb, Jeanne Odom, Daniel Fowler, MD, Ronald Gress, MD, Michael R. Bishop, MD

Blood (2006) 108 (11): 2871.

https://doi.org/10.1182/blood.V108.11.2871.2871

Published: 2006

Journal Articles

Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome May Be Significantly Improved by the Addition of Rituximab to Dose-Adjusted (DA)-EPOCH and Obviates the Need for Radiation: Results from a Prospective Study of 44 Patients.

Kieron Dunleavy, MD, Stefania Pittaluga, MD, John Janik, MD, Nicole Grant, MPH, Margaret Shovlin, RN, Seth Steinberg, PhD, Mark Raffeld, MD, Louis Staudt, MD, PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD, PhD

Blood (2006) 108 (11): 209.

https://doi.org/10.1182/blood.V108.11.209.209

Published: 2006

Journal Articles

DA-EPOCH-R Is Highly Effective in Both BCL-6+ and BCL-6− Untreated De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Study Update and Analysis of Survival Outcomes for Multiple Biomarkers.

Wyndham H. Wilson, MD, PhD, Kieron Dunleavy, MD, Stefania Pittaluga, MD, Nicole Grant, MPH, Margaret Shovlin, RN, Seth Steinberg, PhD, Mark Raffeld, MD, Louis Staudt, MD, PhD, Elaine S. Jaffe, MD, John Janik, MD

Blood (2006) 108 (11): 206.

https://doi.org/10.1182/blood.V108.11.206.206

Published: 2006

Journal Articles

Phase II Clinical Experience with Dose-Adjusted EPOCH-Fludarabine, a Novel Regimen for Targeted Immune Depletion (TID) and Disease Control in Patients with Lymphoid Malignancies Prior to Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RIST).

Robert M. Dean, MD, Daniel Fowler, MD, Wyndham H. Wilson, MD, PhD, Frances Hakim, PhD, Seth Steinberg, PhD, Jeanne Odom, RN, Catherine Chow, MD, Claude Sportes, MD, Juan Gea-Banacloche, MD, Steven Z. Pavletic, MD, Nancy M. Hardy, MD, Ronald Gress, MD, Michael R. Bishop

Blood (2006) 108 (11): 317.

https://doi.org/10.1182/blood.V108.11.317.317

Published: 2006

Journal Articles

Novel Treatment of Burkitt Lymphoma with Dose-Adjusted EPOCH-Rituximab: Preliminary Results Showing Excellent Outcome.

Kieron Dunleavy, MD, Stefania Pittaluga, MD, John Janik, MD, Nicole Grant, MPH, Margaret Shovlin, RN, Richard Little, MD, Robert Yarchoan, MD, Seth Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD, PhD

Blood (2006) 108 (11): 2736.

https://doi.org/10.1182/blood.V108.11.2736.2736

Published: 2006

Journal Articles

Abbreviated Treatment with EPOCH-Rituximab and HAART Suspension Is Highly Effective in AIDS-Related Lymphoma (ARL).

Kieron Dunleavy, MD, Alan S. Wayne, MD, Richard Little, MD, Nicole Grant, MPH, Seth Steinberg, PhD, Elaine S. Jaffe, MD, Stefania Pittaluga, MD, Robert Yarchoan, MD, Jorge Carrasquillo, MD, John Janik, MD, Wyndham H. Wilson, MD, PhD

Blood (2006) 108 (11): 2740.

https://doi.org/10.1182/blood.V108.11.2740.2740

Published: 2006

Journal Articles

Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome Is Significantly Improved by the Addition of Rituximab to Dose Adjusted (DA)-EPOCH and Overcomes the Need for Radiation.

Kieron Dunleavy, MD, Stefania Pittaluga, MD, John Janik, MD, Nicole Grant, RN, Seth Steinberg, PhD, Louis Staudt, MD, PhD, Elaine Jaffe, MD, Wyndham H. Wilson, MD, PhD

Blood (2005) 106 (11): 929.

https://doi.org/10.1182/blood.V106.11.929.929

Published: 2005

NARROW

Incidence, Risks, and Outcomes of Relapse Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma.

Allogeneic Hematopoetic Transplantation for CLL: Results of Combination Chemotherapy as Pre-Transplant Targeted Lymphocyte Depletion on Disease Response, Donor Chimerism, and Transplantation Outcomes.

Clinical, Biochemical, and Radiographic Responses to Rituximab Combined with Liposomal Doxorubicin (R-Dox) in HIV-Infected Patients with Severe Kaposi Sarcoma-Associated Herpes Virus (KSHV) – Associated Multicentric Castleman's Disease.

Targeted Lymphocyte Depletion: A Personalized Approach to Achieve Rapid Complete Donor Chimerism and Enhance Graft-Versus-Tumor Effects Following Reduced Intensity Allogeneic Stem Cell Transplantation for High-Risk Hematologic Malignancies.

Targeted Lymphocyte Depletion Prior to Reduced Intensity Allogeneic Stem Cell Transplantation: A Personalized Approach to Facilitate Engraftment.

Determinants of Platelet Counts in Patients with Chronic Graft Versus Host Disease.

Comparative Clinical and Biological Features of Primary Mediastinal B-Cell Lymphoma (PMBL) and Mediastinal Grey Zone Lymphoma (MGZL).

Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.

Gray Zone Lymphomas: Clinical and Histological Characteristics and Treatment with Dose-Adjusted-EPOCH-R

Long-Term Outcome of AIDS-Related Lymphoma Treated with Abbreviated Cycles of EPOCH-RR: A Prospective Study of 40 Patients

Early Results of a Clinical Trial Using Targeted Oncolytic Virotherapy in Kaposi Sarcoma Herpes Virus (KSHV) Associated Multicentric Castleman’s Disease (MCD).

Burden of Illness in Chronic Graft vs. Host Disease - A Prospective Cohort Study.

Soluble BAFF Is Elevated Following Allogeneic SCT but Is Not an Early Predictor for the Development of cGVHD.

Ex-Vivo Reduction of Allograft T Cell Dose Does Not Prevent Acute Graft-vs-Host Disease after Reduced-Intensity Hematopoietic Stem Cell Transplantation.

Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome May Be Significantly Improved by the Addition of Rituximab to Dose-Adjusted (DA)-EPOCH and Obviates the Need for Radiation: Results from a Prospective Study of 44 Patients.

DA-EPOCH-R Is Highly Effective in Both BCL-6+ and BCL-6− Untreated De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Study Update and Analysis of Survival Outcomes for Multiple Biomarkers.

Phase II Clinical Experience with Dose-Adjusted EPOCH-Fludarabine, a Novel Regimen for Targeted Immune Depletion (TID) and Disease Control in Patients with Lymphoid Malignancies Prior to Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RIST).

Novel Treatment of Burkitt Lymphoma with Dose-Adjusted EPOCH-Rituximab: Preliminary Results Showing Excellent Outcome.

Abbreviated Treatment with EPOCH-Rituximab and HAART Suspension Is Highly Effective in AIDS-Related Lymphoma (ARL).

Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome Is Significantly Improved by the Addition of Rituximab to Dose Adjusted (DA)-EPOCH and Overcomes the Need for Radiation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only